CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection
- Data provided further evidence on immunogenicity and protective efficacy of CVnCoV
- Induction of robust antibody and T cell responses at lower dose than tested in Phase 3 trial
- Full lung protection of CVnCoV-vaccinated animals during SARS-CoV-2 challenge infection
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. Furthermore, rhesus macaques were shown to be protected from challenge infection with SARS-CoV-2 following vaccination with 8µg of CVnCoV. The data provided important evidence on the immunogenicity and protective efficacy of CVnCoV at low doses, supporting the ongoing international clinical Phase 2b/3 efficacy study applying a 12µg dose. The full manuscript of the preclinical data is available on the pre-print server bioRxiv.